Month: April 2024

Conference call to be webcast live at 2 p.m. PT / 5 p.m. ET SAN FRANCISCO, April 12, 2024 (GLOBE NEWSWIRE) — Udemy (Nasdaq: UDMY), a leading online skills marketplace and learning platform, today announced it will report its first quarter 2024 financial results after the close of market on Thursday, May 2, 2024. Udemy will host a live conference call and webcast to discuss the results that afternoon at 2 p.m. PT / 5 p.m. ET. A link to the live webcast and recorded replay of the conference call will be available on the “Quarterly Results” section of Udemy’s Investor Relations website at https://investors.udemy.com/. The live call may also be accessed toll-free via telephone at (833) 630-1963 domestically and (412) 317-5702 internationally. The archived replay of the webcast will be available for approximately one year. About UdemyUdemy...

U.S. Factories and experienced staff support broad school recovery and related demand for school furniture Vertical control of order-to-cash cycle generates strong operating and financial efficiencies, with most metrics at historic highsNet Income reaches $21.9 million vs. $16.5 million in prior year Full Year Gross Margin expands to 43.1% vs. 36.9% in prior year Cash flow from operations reaches $27.0 million vs. $(3.8 million) in prior year due to combined operating income and balancing of post-pandemic inventories Forward indicator of “Shipments plus Backlog” reaches record $317.6 million vs. $289.6 million last year Company is effectively debt-free at year endTORRANCE, Calif., April 12, 2024 (GLOBE NEWSWIRE) — Virco Mfg. Corporation (NASDAQ: VIRC), the leading manufacturer and supplier of moveable furniture and equipment...

April 12, 2024 SBM Offshore is pleased to announce that all resolutions were adopted as proposed during the Annual General Meeting of April 12, 2024. The adopted resolutions include the appointment of Patrick Jager as member of the Supervisory Board. Shareholders also voted in favor of the proposed all cash dividend of US$150 million, which represents a dividend distribution of US$0.8336 per ordinary share. Dividends will be paid in Euros using the exchange rate on February 28, 2024 of 1.0895, which will result in a payout of €0.7651 per ordinary share. The cash dividend is payable on May 10, 2024 to all shareholders of record as at April 16, 2024 through the bank or broker administering the shares. ABN AMRO is responsible for executing the dividend payment on behalf of SBM Offshore and offers the Company’s shareholders the option to participate...

ANNOUNCEMENT NO. 261Clarification of guidance for revenue and lower than expected operating profit in the 2023/24 financial year According to the preliminary figures, revenue in the third quarter of 2023/24 was DKK 98.9 million and in the first nine months of 2023/24 DKK 298.2 million. Based on the development in the third quarter of 2023/24 and the expectations for the remaining part of the financial year, expectations for revenue for the 2023/24 financial year are clarified. Hence, revenue in 2023/24 is expected to be in the DKK 400-415 million range against previously announced DKK 400-435 million and thus still within the most recently announced range. Earnings in the third quarter of 2023/24 have been affected by one-off costs in connection with organizational changes, and, among other things, as a result of this, an operating...

Signifies the first major step towards the application process for the certification of its Mango ED oral dissolvable products by Mexico’s health governing agency, COFEPRIS Dallas, Texas, April 12, 2024 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the area of erectile dysfunction (ED), hair growth and hormone replacement therapies is excited to announce that its subsidiary, MangoRx Mexico S.A. de C.V. (“MangoRx Mexico”), has secured and executed a technical agreement with Emifarma S.A. de C.V (“Emifarma”) for the initial stages of development and testing (Bioequivalence and Accelerated Stability, required to obtain registry from COFEPRIS) of the Company’s Mango ED products intended for...